Is Drug Treatment for Dementia Followed Up in Primary Care? A Swedish Study of Dementia Clinics and Referring Primary Care Centres

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sonde, Lars ^a,b   Johnell, Kristina ^b,c  

^a FOU nu Research and Development Centre   (Sweden)

^b STOCKHOLM GERONTOLOGY RESEARCH CENTER   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; DEMENTIA; DRUG USE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; MULTIINFARCT DEMENTIA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SWEDEN; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA; DEMENTIA, VASCULAR; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MEDICAL RECORDS; MEMANTINE; NOOTROPIC AGENTS; PHENYLCARBAMATES; PHYSICIAN'S PRACTICE PATTERNS; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME;

EID: 84874259348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057161     Document Type: Article

References (19)

1. Religa D, Winblad B, (2003) Therapeutic strategies for Alzheimer's disease based on new molecular mechanisms. Acta Neurobiol Exp (Wars) 63: 393-6.
2. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, et al. (2001) Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 16: 653-66.
3. Christensen DD, Lin P, (2007) Practical treatment strategies for patients with Alzheimer's disease. J Fam Pract 56: 17-23.
4. The Swedish National Board of Health and Welfare (2010) Guidelines for dementia care. Socialstyrelsen.
5. Johnell K, Ringbäck Weitoft G, Fastbom J, (2008) Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord 25: 54-9.
6. Birks J, (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst rev 25: CD005593.
7. Rodda J, Carter J, (2012) Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 344: e2986.
8. Kavirajan H, Schneider LS, (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6 (9): 782-92.
9. Thompson S, Lanctot KL, Herrmann N, (2004) The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 3: 425-40.
10. Herrmann N, Li A, Lanctôt K, (2011) Memantinee in dementia: a review of the current evidence. Expert Opin Pharmacother 12 (5): 787-800.
11. Geldmacher DS, (2003) Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician. Prim Care Companion J Clin Psychiatry 5: 251-9.
12. Krebs EE, Bair MJ, Carey TS, Weinberger M, (2010) Documentation of pain care processes does not accurately reflect pain management delivered in primary care. J Gen Intern Med 25: 194-9.
13. Purandare N, Swarbrick C, Fischer A, Burns A, (2006) Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 21: 961-4.
14. Jedenius E, Johnell K, Fastbom J, Stromqvist J, Winblad B, et al. (2011) Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population. Scand J Prim Health Care 29: 181-6.
15. Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B, (2008) Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis. Dement Geriatr Cogn Disord 26 (5): 458-66.
16. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frölich L, et al. (2009) Safety and efficacy of galantamine in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 8 (1): 39-47.
17. Santoro A, Siviero P, Minicuci N Bellavista E, Mishto M, et al. (2010) Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs 24: 163-176.
18. Miyamoto M, Kodama C, Kinoshita T, Yamashita F, Hidaka S, et al. (2009) Dementia and mild cognitive impairment among non-responders to a community survey. J Clin Neurosci 16: 270-6.
19. Hardie JA, Bakke PS, Morkve O, (2003) Non-response bias in a postal questionnaire survey on respiratory health in the old and very old. Scand J Public Health 31: 411-7.